NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced today that it will participate in the Planet MicroCap Las Vegas 2026 Conference from June 17-18, 2026. President and CEO Dave Rosa will attend the conference in Las Vegas, Nevada, where he is scheduled to host one-on-one meetings with institutional investors and deliver a company presentation on Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time. The presentation will take place in TRACK 6 - Raphael 3 and will include commercialization updates and anticipated milestones for the OneRF platform, which is designed for treatment of the brain, pain, and advanced drug delivery.
Rosa also participated in a CEO interview with Planet MicroCap host Robert Kraft ahead of the conference, which can be viewed here. The conference webcast will be available here, and additional information can be found on the conference website here. For those interested in scheduling a meeting with management, requests can be emailed to NMTC@mzgroup.us or directed to Chris Tyson at (949) 491-8235.
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The presentation at the Planet MicroCap conference is significant as it provides a platform for NeuroOne to update investors on its commercialization progress and future milestones. The OneRF platform represents a key growth driver for the company, with potential applications in treating brain disorders, chronic pain, and enabling advanced drug delivery. By highlighting these developments, NeuroOne seeks to attract institutional investment to support its ongoing research and market expansion.
Caution: Federal law restricts this device to sale by or on the order of a physician. For more information about NeuroOne, visit nmtc1.com.
